NextenBio Seeks Domestic Partners to Develop Platform Technology for Type 2 Diabetes

[Asia Economy Reporter Jang Hyowon] Nexten Bio recently announced on the 22nd that it is seeking domestic partners who can collaborate on pipeline development for diabetes, obesity, and digestive disorders with Rossbio Therapeutics (hereinafter Rossbio), in which it acquired a 50% stake.

Rossbio, in which Nexten Bio is the largest shareholder, is reportedly receiving active interest from global pharmaceutical companies including Novo Nordisk for its microRNA (miRNA)-based diabetes treatment substances and technologies.

The company is known to be looking for domestic pharmaceutical and bio companies that can accelerate clinical trials and pipeline research and development of treatments for diabetes, obesity, and non-alcoholic fatty liver disease by combining the patents and know-how of Rossbio’s miRNA-based pipelines.

Nexten Bio stated, “Given the characteristics of the pharmaceutical and bio industry led by global big pharma, there are not many ways for bio venture companies to survive, and ultimately they have no choice but to transfer technology to big pharma. We want Rossbio, which possesses miRNA-based core technology, to prepare for co-growth with domestic pharmaceutical and bio companies.”

They added, “Korea is entering an aging society, and the increase in diabetes and obesity populations is closely related to aging. We aim to develop new drugs that can be used as new treatment options for domestic diabetes patients and will work closely with domestic pharmaceutical and bio companies.”

Furthermore, they said, “We will continue to seek companies that can jointly develop platform technologies and conduct joint research not only for diabetes treatments but also for obesity, non-alcoholic fatty liver disease, and COVID-19 treatments.”

This content was produced with the assistance of AI translation services.